Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most significant correlation was that the A allele and AA genotype of CYP2D6 rs1065852 were associated with increased risk of LC development (adjusted odds ratio [OR] = 1.35, 95% confidence interval [95%CI] = 1.13-1.60, P = 9.04e-4; OR = 1.83, 95%CI = 1.29-2.59, P = 0.001 respectively).
|
31264381 |
2019 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present meta-analysis supported the positive association of CYP2D6 T188C variant with lung cancer in the Chinese.
|
23558964 |
2013 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report the involvement of a three-order interaction between CYP1A1, CYP2A6, and CYP2D6 polymorphisms in lung cancer risk in people in Central South China, although no relationship between lung cancer risk and individual gene polymorphisms was found.
|
23471717 |
2013 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study is the first to be carried out on a North Indian population, and, although small, suggests that CYP1A1 and CYP2D6 polymorphisms might have a role in determining the risk for lung cancer and should be investigated further.
|
14602525 |
2004 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several independent studies indicate that the CYP2D6 metabolic status is a secondary factor in the risk of developing lung cancer, with individuals with high activity being at increased risk.
|
11474250 |
2001 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer risks for the CYP2D6 PM genotype amongst light smokers (tobacco consumption </=20 g/day) or heavy smokers (>20 g/day) were not significantly different.
|
10974631 |
2000 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The data did not suggest a substantial interaction effect between GSTM1 and CYP2D6 polymorphisms and the risk of lung cancer.
|
10521684 |
1999 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Taking this new information into account, we have reconsidered the potential influence of CYP2D6 polymorphism in lung cancer susceptibility by performing a comparative analysis of the overall mutational spectrum of CYP2D6 and of the rearrangements of CYP2D in 249 patients with lung cancer and in 265 control individuals matched on age, sex, hospital and residence area.
|
9511176 |
1998 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the concept that genetic polymorphisms may contribute to differential lung cancer susceptibility is sound, these data do not support the role of CYP2D6 as a marker for elevated lung cancer risk.
|
9521436 |
1998 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, poor metabolizers with respect to CYP2D6 show a small decrease in susceptibility to lung cancer compared with extensive metabolizers and its is hard to justify further studies.
|
9682268 |
1998 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also examined the possible role of additional copies of the CYP2D6 gene, which lead to enhanced CYP2D6 activity, in increasing lung cancer risk.
|
9214604 |
1997 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The cytochromes P-450 (CYPs) are responsible for the activation mechanism, and polymorphisms of the CYPs (CYP1A1, CYP2D6, and possibly CYP2E1) are known to be related to increased susceptibility to smoking related Kreyberg type I lung cancer.
|
9439147 |
1997 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No association was found between the CYP2D6 oxidation polymorphism and lung cancer risk when sample size bias was taken into account.
|
9049580 |
1997 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, the CYP2D6(C) allele does not encode a completely inactivating mutation, and the suggestion of a role for this variant allele in the risk for specific histologic types of lung cancer justifies further investigation.
|
9194027 |
1997 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Present studies on increased risk of smoking-related lung cancer associated with phenotypic or genotypic variation of the genes encoding for CYP1A1 or CYP2D6 enzymes are summarized.
|
9255556 |
1997 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results do not confirm an earlier report that this CYP2D6*9 mutant allele may be an additional risk factor for the development of lung cancer.
|
8895499 |
1996 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The interaction between CYP2D6 activity and tobacco was weaker for larynx cancer than that reported previously for lung cancer.
|
8877058 |
1996 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We focus on variability in studies of lung cancer and the CYP2D6 gene (debrisoquine metabolic phenotype) as an instructive case and we propose some sources for this heterogeneity.
|
7581482 |
1995 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altered phenotypes and genotypes in the CYP subfamilies CYP1A1, CYP2D6 and CYP2E1 have been associated with tobacco smoke-induced lung cancer and other cancers.
|
7607565 |
1995 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure.
|
7586196 |
1995 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Higher 7-methyl-dGMP adduct levels were associated with CYP2D6 genotypes (P = .01), consistent with the reports of the increased risk of lung cancer associated with this genotype.
|
7666479 |
1995 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This suggests that the CYP2D6(C) allele could be considered as an additional risk factor because carriers could have higher susceptibility to the development of lung cancer.
|
8299311 |
1994 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A PCR-based test was designed for this new allele (designated CYP2D6(T)) and 236 unrelated individuals from a lung cancer case control study were tested for the presence of the CYP2D6(T) mutation.
|
7951238 |
1994 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Case-control studies that assess the effects of CYPIID6 on lung cancer risk have consistently shown a mildly decreased risk for lung cancer among poor metabolizers.
|
1302563 |
1993 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer.
|
7908263 |
1993 |